Abstract:Introduction Patients with Fontan circulation, require screening for liver cirrhosis and malignancy, to which they are susceptible with time. Surveillance biopsies reveal nearly all adult Fontan patients develop asymptomatic fibrosis, and a majority have abnormal liver function tests (LFTs). This presents significant financial healthcare burden and psychological stress with testing for patients. Objective We aim to present "real-world" liver screening data, from a leading Adult Congenital Heart Disease (ACHD) centre, to propose a cost-reducing testing regimen, which delivers effective screening, while taking account of the challenges of current guidance, patient compliance, and clinical practice. Methods We analysed liver screening data for Fontan patients at a leading ACHD centre, focusing on biochemical tests (bilirubin, ALT, GGT) and imaging. We evaluated the 10-year financial impact of current practices, versus a hypothetical model based on age and risk factors, alongside biannual and annual screening strategies. Tariffs for biochemical test were provided by the local pathology service and we used NHS HRG tariffs for imaging and phlebotomy. Results We included data from 114 patients with a Fontan circulation (median age 32 range 19-56, 42% females). Eighteen patients developed liver cirrhosis diagnosed on imaging (median age 32, range 22-48). None developed hepatocellular carcinoma. A lack of clear and agreed local screening guidelines (over years) resulted in vastly different investigations for FALD, with inconsistent time intervals for testing. Bilirubin was elevated in 59% (55% in age 18-29), ALT was elevated in 41% (31% in age 18-29), GGT was elevated in 83% (80% in age 18-29). We found 3 cases of cirrhosis in the age group 18-29, all with hypoplastic left heart; 4 cases of cirrhosis in age group 30-34 - all had significant comorbidities; 33% had normal bilirubin, LFT and GGT, potentially not requiring further screening until the age of 35. Eleven patients (22%) age 35+ had confirmed cirrhosis (Figure 1). Performing full FALD screening with biochemistry and liver ultrasound every 12-24 months would increase the cost of screening three- to six-fold. We propose rationalising liver screening by age and underlying risk (Figure 2) to minimise the economic burden and equally the psychological impact of frequent testing on patients. Conclusions Our analysis underscores the necessity for an optimised liver screening protocol in Fontan patients, balancing diagnostic accuracy with cost-efficiency. By integrating this data, we have identified a pathway to streamline screening, tailoring it to individual risk profiles and age groups, thereby reducing unnecessary tests, lowering costs and reducing the impact of testing on patients. This approach not only fosters better patient care, but also provides a framework for developing clearer, cost-effective screening guidelines, to monitor liver health, in these complex CHD patients.

Predicting and maybe preventing Fontan-associated liver disease

Fontan-Associated Liver Disease: A Review

Effect of liver abnormalities on mortality in Fontan patients: a systematic review and meta-analysis

A single-cell multiomics profile of Fontan-associated liver disease

Fontan Associated Liver Disease (FALD) - When Should We Consider Combined Heart-lung Transplant

S2132 Demographic and Geographic Variations in Fontan-Associated Liver Disease Among Pediatric Patients: A Nationwide Analysis

Prediction of Fontan-Associated Liver Disease Using a Novel Cine Magnetic Resonance Imaging "Vortex Flow Map" in the Right Atrium

Severity of Fontan-Associated Liver Disease Correlates with Fontan Hemodynamics

Understanding the Fontan Procedure in Congenital Heart Disease Patients and the Importance of Early Hepatology Referrals: A Case Study

Intrahepatic Transcriptomics Differentiate Advanced Fibrosis and Clinical Outcomes in Adults With Fontan Circulation

Single-cell multiomics guided mechanistic understanding of Fontan-associated liver disease

Histopathological Spectrum and Molecular Characterization of Liver Tumors in the Setting of Fontan-Associated Liver Disease

Early detection of liver fibrosis in patients with Fontan circulation using multiparametric magnetic resonance imaging

Mortality and morbidity after combined heart and liver transplantation in the failing Fontan: An updated dual center retrospective study

Morbidity and mortality in adults with a Fontan circulation beyond the fourth decade of life

Optimising liver screening in patients with a Fontan circulation: a cost-effective approach to detection of Fontan associated liver disease which enhances patient care

S1922 Evaluating Outcomes and Perioperative Complications of Combined Heart and Liver Transplantation in Patients With Failing Fontan Physiology: A Systematic Review

Liver fibrosis detected by diffusion-weighted magnetic resonance imaging and its functional correlates in Fontan patients

Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021

Evaluating the Longevity of the Fontan Pathway

Meta‐analysis: Incidence of cirrhosis and hepatocellular carcinoma in patients with Fontan palliation